ITOS News and Press, iTeos Therapeutics Inc. From 05/12/22

Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with BMS’s novel CELMoD agent, iberdomide. Enrolling patients in the biomarker cohort in an ongoing clinical trial of in...

Gainers: Trecora Resources (TREC) +27%. Golden Matrix Group (GMGI) +24%. Charge Enterprises (CRGE) +21%. Inspired Entertainment (INSE) +20%. Celsius Holdings (CELH) +20%. QualTek Services (QTEK) +18%. Blue Water Vaccines (BWV) +18%. Grocery Outlet Holding (GO) +17%. H&R Block (HRB) +17%. ...

Gainers: Blue Water Vaccines (BWV) +18%. Oscar Health (OSCR) +13%. Veru (VERU) +10%. Zai Lab (ZLAB) +8%. Better Therapeutics (BTTX) +6%. Losers: Inovio Pharmaceuticals (INO) -32%. iTeos Therapeutics (ITOS) -32%. Arcus Biosciences (RCUS) -28%. Akand...

A group of pharma companies focused on ant-TIGIT class of drugs are trading sharply lower in the pre-market Wednesday after French pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced that a similar treatment failed in a late-stage trial for non-small cell lung cancer (NSCLC). The global ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioNTech ( BNTX ) rose to fame with the tech that delivered the Pfizer ( PFE ) vaccine, but there’s more there than just the vaccine. BioCryst Pharmaceuticals ( BCRX ) is a commercial-stage biote...

Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...

Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibody In preclinical studies and in blood samples from patients with advanced cancers, tre...

iTeos Therapeutics press release (NASDAQ:ITOS): Q4 GAAP EPS of -$5.24. The Company’s cash and cash equivalent position was $848.5 million as of December 31, 2021, as compared to $336.3 million as of December 31, 2020. Cash balance provides runway into 2026. For further details see: ...

- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab -gxly) and EOS-448 combination trial and announced plans to initiate multiple registration-directed clinical trials with this combination - Initiati...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, to...